Displaying all 5 publications

Abstract:
Sort:
  1. Jain SK
    Med J Malaysia, 1982 Mar;37(1):88-9.
    PMID: 7121356
    The role of multiple pleural biopsies in malignant pleural effusion to achieve better diagnostic yield was evaluated. The specific diagnosis was established in 43.8 percent (14/32) of cases on first biopsy, and improved to 93.8 percent (30/32) of cases by three biopsies. The contribution of multiple biopsies was stressed.
    Matched MeSH terms: Pleural Neoplasms/pathology*
  2. Lee CE, Zanariah H, Masni M, Pau KK
    Med J Malaysia, 2010 Mar;65(1):72-4.
    PMID: 21265256 MyJurnal
    We report a case of a 61 year-old man who presented with refractory non-insulin mediated hypoglycaemia. A chest radiograph showed a right lung opacity, which was confirmed as a large intra-thoracic mass by computed tomography (CT) of the thorax. CT-guided biopsy with histological examination revealed features of a solitary fibrous tumour of low malignant potential. We discuss the association of solitary fibrous tumour of the pleura (SFTP) with hypoglycaemia, and the management of such rare tumours.
    Matched MeSH terms: Pleural Neoplasms/pathology
  3. De Rienzo A, Archer MA, Yeap BY, Dao N, Sciaranghella D, Sideris AC, et al.
    Cancer Res, 2016 Jan 15;76(2):319-28.
    PMID: 26554828 DOI: 10.1158/0008-5472.CAN-15-0751
    Malignant pleural mesothelioma (MPM) is an aggressive cancer that occurs more frequently in men, but is associated with longer survival in women. Insight into the survival advantage of female patients may advance the molecular understanding of MPM and identify therapeutic interventions that will improve the prognosis for all MPM patients. In this study, we performed whole-genome sequencing of tumor specimens from 10 MPM patients and matched control samples to identify potential driver mutations underlying MPM. We identified molecular differences associated with gender and histology. Specifically, single-nucleotide variants of BAP1 were observed in 21% of cases, with lower mutation rates observed in sarcomatoid MPM (P < 0.001). Chromosome 22q loss was more frequently associated with the epithelioid than that nonepitheliod histology (P = 0.037), whereas CDKN2A deletions occurred more frequently in nonepithelioid subtypes among men (P = 0.021) and were correlated with shorter overall survival for the entire cohort (P = 0.002) and for men (P = 0.012). Furthermore, women were more likely to harbor TP53 mutations (P = 0.004). Novel mutations were found in genes associated with the integrin-linked kinase pathway, including MYH9 and RHOA. Moreover, expression levels of BAP1, MYH9, and RHOA were significantly higher in nonepithelioid tumors, and were associated with significant reduction in survival of the entire cohort and across gender subgroups. Collectively, our findings indicate that diverse mechanisms highly related to gender and histology appear to drive MPM.
    Matched MeSH terms: Pleural Neoplasms/pathology
  4. Jennings CJ, Murer B, O'Grady A, Hearn LM, Harvey BJ, Kay EW, et al.
    Br. J. Cancer, 2015 Jun 30;113(1):69-75.
    PMID: 26057448 DOI: 10.1038/bjc.2015.187
    Malignant pleural mesothelioma (MPM) is a rare and essentially incurable malignancy most often linked with occupational exposure to asbestos fibres. In common with other malignancies, the development and progression of MPM is associated with extensive dysregulation of cell cycle checkpoint proteins that modulate cell proliferation, apoptosis, DNA repair and senescence.
    Matched MeSH terms: Pleural Neoplasms/pathology
  5. Jennings CJ, Zainal N, Dahlan IM, Kay EW, Harvey BJ, Thomas W
    Anticancer Res, 2016 11;36(11):5905-5913.
    PMID: 27793915
    Malignant pleural mesothelioma (MPM) is a rare but highly aggressive malignancy most often associated with exposure to asbestos. Recent evidence points to oestrogen receptor (ER)-β having a tumour-suppressor role in MPM progression, and this raises the question of whether selective modulators of ERs could play a role in augmenting MPM therapy.
    Matched MeSH terms: Pleural Neoplasms/pathology*
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links